Abstract
Schistosomiasis is a devastating worldwide widespread tropical disease that currently affects more than 230 million people, making it an issue of great socioeconomic and public health importance. Unfortunatelly there is a single drug for the treatment of all forms of schistosomiasis, praziquantel, which was introduced in therapy in 1980. The article goes by antimony compounds, emetine, hydantoin, nitrofurans, lucanthone, hycanthone, oxamniquine derivatives and organophosphates until it finally gets to praziquantel derivatives. The intent of this review is to provide a panorama of drugs that were and are being used in human chemotherapy looking to the past to improve rational design drugs in the future. Not only clinical used compounds will be shown but also synthesized and tested compounds in vitro and in vivo in animal models which haven’t yet to be used in humans. Prospects for drug discovery and vaccines to be used in the treatment and prevention of schistosomiasis, clinical trials, concerns about the resistance/decreased effectiveness of the treatment, and patent database will also be discussed. At the end of the review the reader will notice that much has been done but much still needs to be done yet.
Keywords: Anti-schistosoma therapies, schistosomiasis, chemical structure of compounds, parasitic disease, resistance to treatment, CHEMOTHERAPY, DEHYDROEMETINE, 5-diphenylhydantoin, in vitro
Mini-Reviews in Medicinal Chemistry
Title:The Evolution of Drugs on Schistosoma Treatment: Looking to the Past to Improve the Future
Volume: 13 Issue: 4
Author(s): Maira Galdino da Rocha Pitta, Marina Galdino da Rocha Pitta, Moacyr Jesus Barreto de Melo Rego and Suely Lins Galdino
Affiliation:
Keywords: Anti-schistosoma therapies, schistosomiasis, chemical structure of compounds, parasitic disease, resistance to treatment, CHEMOTHERAPY, DEHYDROEMETINE, 5-diphenylhydantoin, in vitro
Abstract: Schistosomiasis is a devastating worldwide widespread tropical disease that currently affects more than 230 million people, making it an issue of great socioeconomic and public health importance. Unfortunatelly there is a single drug for the treatment of all forms of schistosomiasis, praziquantel, which was introduced in therapy in 1980. The article goes by antimony compounds, emetine, hydantoin, nitrofurans, lucanthone, hycanthone, oxamniquine derivatives and organophosphates until it finally gets to praziquantel derivatives. The intent of this review is to provide a panorama of drugs that were and are being used in human chemotherapy looking to the past to improve rational design drugs in the future. Not only clinical used compounds will be shown but also synthesized and tested compounds in vitro and in vivo in animal models which haven’t yet to be used in humans. Prospects for drug discovery and vaccines to be used in the treatment and prevention of schistosomiasis, clinical trials, concerns about the resistance/decreased effectiveness of the treatment, and patent database will also be discussed. At the end of the review the reader will notice that much has been done but much still needs to be done yet.
Export Options
About this article
Cite this article as:
Galdino da Rocha Pitta Maira, Galdino da Rocha Pitta Marina, Jesus Barreto de Melo Rego Moacyr and Lins Galdino Suely, The Evolution of Drugs on Schistosoma Treatment: Looking to the Past to Improve the Future, Mini-Reviews in Medicinal Chemistry 2013; 13 (4) . https://dx.doi.org/10.2174/1389557511313040003
DOI https://dx.doi.org/10.2174/1389557511313040003 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Misfolding of Apoprotein B-100, LDL Aggregation and 17-β -estradiol in Atherogenesis
Current Medicinal Chemistry Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
Current Gene Therapy Nucleic Acids Delivery Systems: A Challenge for Pharmaceutical Technologists
Current Drug Metabolism Edging Toward Personalized Medicine
Current Pharmacogenomics Invasive aspergillosis: adjunctive combination therapy
Mini-Reviews in Medicinal Chemistry TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis
Current Pharmaceutical Design The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry Emerging Therapies for Diabetic Neuropathy: A Clinical Overview
Current Diabetes Reviews Genetic Engineering in Allotransplantation of Vascularized Organs
Current Gene Therapy Regulation of Gastric Nesfatin-1/NUCB2
Current Pharmaceutical Design Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Glutathione Peroxidase: A Potential Marker for the Most Common Diseases and Disorders
Recent Patents on Biomarkers Targeting Aldose Reductase for the Treatment of Cancer
Current Cancer Drug Targets Proline-Rich Peptides: Multifunctional Bioactive Molecules as New Potential Therapeutic Drugs
Current Protein & Peptide Science Understanding of and Possible Strategies to Avian Influenza Outbreak
Current Pharmaceutical Biotechnology Pulmonary Hypertension in the Critically Ill
Current Hypertension Reviews A Review on Rheumatoid Arthritis Interventions and Current Developments
Current Drug Targets Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection
Current Drug Metabolism